Indispensable roles of OX40L-derived signal and epistatic genetic effect in immune-mediated pathogenesis of spontaneous pulmonary hypertension

BMC Immunology

Volumn 12, Issue , 2011, Pages

  Rabieyousefi, Moloud ^a   Soroosh, Pejman ^a,e   Satoh, Kimio ^a   Date, Fumiko ^a   Ishii, Naoto ^a,d   Yamashita, Masahiro ^a   Oka, Masahiko ^b   McMurtry, Ivan F ^b   Shimokawa, Hiroaki ^a   Nose, Masato ^c   Sugamura, Kazuo ^a   Ono, Masao ^a,d  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^c EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OX40 LIGAND; TUMOR NECROSIS FACTOR; CYTOKINE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CHROMOSOME 5; GENE LOCUS; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; HEREDITY; HISTOPATHOLOGY; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PHYSICAL EXAMINATION; PULMONARY HYPERTENSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD PRESSURE; C57BL MOUSE; CD4+ T LYMPHOCYTE; FEMALE; GENE EXPRESSION; GENETIC EPISTASIS; GENETIC PREDISPOSITION; GENETICS; HEART RIGHT VENTRICLE HYPERTROPHY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LUNG; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHENOTYPE; QUANTITATIVE TRAIT LOCUS;

ANIMALS; BLOOD PRESSURE; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; EPISTASIS, GENETIC; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; IMMUNOLOGIC MEMORY; LUNG; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; OX40 LIGAND; PHENOTYPE; QUANTITATIVE TRAIT LOCI; SIGNAL TRANSDUCTION;

EID: 83455195470     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-12-67     Document Type: Article

References (48)

1. Veeraraghavan S, Koss MN, Sharma OP. Pulmonary veno-occlusive disease. Curr Opin Pulm Med 1999, 5(5):310-313. 10.1097/00063198-199909000-00008, 10461536.
2. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003, 22(2):358-363. 10.1183/09031936.03.00038903, 12952274.
3. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43(12 Suppl S):13S-24S.
4. Golembeski SM, West J, Tada Y, Fagan KA. Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest 2005, 128(6 Suppl):572S-573S.
5. Hoshino T, Kato S, Oka N, Imaoka H, Kinoshita T, Takei S, Kitasato Y, Kawayama T, Imaizumi T, Yamada K, et al. Pulmonary Inflammation and Emphysema: Role of the Cytokines IL-18 and IL-13. Am J Respir Crit Care Med 2007, 176(1):49-62. 10.1164/rccm.200603-316OC, 17400729.
6. Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005, 26(6):1110-1118. 10.1183/09031936.05.00045705, 16319344.
7. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, Scerbavicius R, Burns N, Cool C, Wood K, Parr JE, Boackle SA, Voelkel NF. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med 2007, 175(12):1280-1289. 10.1164/rccm.200608-1189OC, 2176089, 17413127.
8. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996, 14:233-258. 10.1146/annurev.immunol.14.1.233, 8717514.
9. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?. Nat Rev Immunol 2003, 3(8):609-620. 10.1038/nri1148, 12974476.
10. Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 2004, 4(6):420-431. 10.1038/nri1371, 15173831.
11. Mestas J, Crampton SP, Hori T, Hughes CC. Endothelial cell co-stimulation through OX40 augments and prolongs T cell cytokine synthesis by stabilization of cytokine mRNA. Int Immunol 2005, 17(6):737-747. 10.1093/intimm/dxh255, 15908450.
12. Kotani A, Hori T, Matsumura Y, Uchiyama T. Signaling of gp34 (OX40 ligand) induces vascular endothelial cells to produce a CC chemokine RANTES/CCL5. Immunol Lett 2002, 84(1):1-7. 10.1016/S0165-2478(02)00082-2, 12161277.
13. Gramaglia I, Weinberg AD, Lemon M, Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998, 161(12):6510-6517.
14. Murata K, Ishii N, Takano H, Miura S, Ndhlovu LC, Nose M, Noda T, Sugamura K. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med 2000, 191(2):365-374. 10.1084/jem.191.2.365, 2195745, 10637280.
15. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001, 15(3):445-455. 10.1016/S1074-7613(01)00191-1, 11567634.
16. Soroosh P, Ine S, Sugamura K, Ishii N. OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity. J Immunol 2006, 176(10):5975-5987.
17. Soroosh P, Ine S, Sugamura K, Ishii N. Differential Requirements for OX40 Signals on Generation of Effector and Central Memory CD4+ T Cells. J Immunol 2007, 179(8):5014-5023.
18. Maxwell JR, Weinberg A, Prell RA, Vella AT. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol 2000, 164(1):107-112.
19. Murata K, Nose M, Ndhlovu LC, Sato T, Sugamura K, Ishii N. Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J Immunol 2002, 169(8):4628-4636.
20. Satoh K, Kagaya Y, Nakano M, Ito Y, Ohta J, Tada H, Karibe A, Minegishi N, Suzuki N, Yamamoto M, et al. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 2006, 113(11):1442-1450. 10.1161/CIRCULATIONAHA.105.583732, 16534010.
21. Marzo AL, Vezys V, Williams K, Tough DF, Lefrancois L. Tissue-level regulation of Th1 and Th2 primary and memory CD4 T cells in response to Listeria infection. J Immunol 2002, 168(9):4504-4510.
22. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 1995, 11(3):241-247. 10.1038/ng1195-241, 7581446.
23. Morris JA, Gardner MJ. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed) 1988, 296(6632):1313-1316.
24. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562. 10.1146/annurev.immunol.21.120601.141122, 15032588.
25. Hadeiba H, Locksley RM. Lung CD25 CD4 regulatory T cells suppress type 2 immune responses but not bronchial hyperreactivity. J Immunol 2003, 170(11):5502-5510.
26. Lewkowich IP, Herman NS, Schleifer KW, Dance MP, Chen BL, Dienger KM, Sproles AA, Shah JS, Kohl J, Belkaid Y, et al. CD4+CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J Exp Med 2005, 202(11):1549-1561. 10.1084/jem.20051506, 2213331, 16314437.
27. McKinley L, Logar AJ, McAllister F, Zheng M, Steele C, Kolls JK. Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia. J Immunol 2006, 177(9):6215-6226.
28. Bodolay E, Csipo I, Gal I, Sipka S, Gyimesi E, Szekanecz Z, Szegedi G. Anti-endothelial cell antibodies in mixed connective tissue disease: frequency and association with clinical symptoms. Clin Exp Rheumatol 2004, 22(4):409-415.
29. Vegh J, Szodoray P, Kappelmayer J, Csipo I, Udvardy M, Lakos G, Aleksza M, Soltesz P, Szilagyi A, Zeher M, et al. Clinical and immunoserological characteristics of mixed connective tissue disease associated with pulmonary arterial hypertension. Scand J Immunol 2006, 64(1):69-76. 10.1111/j.1365-3083.2006.01770.x, 16784493.
30. Wang X, Ria M, Kelmenson PM, Eriksson P, Higgins DC, Samnegard A, Petros C, Rollins J, Bennet AM, Wiman B, et al. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet 2005, 37(4):365-372. 10.1038/ng1524, 15750594.
31. van Wanrooij EJ, van Puijvelde GH, de Vos P, Yagita H, van Berkel TJ, Kuiper J. Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007, 27(1):204-210. 10.1161/01.ATV.0000251007.07648.81, 17068285.
32. Takeda I, Ine S, Killeen N, Ndhlovu LC, Murata K, Satomi S, Sugamura K, Ishii N. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 2004, 172(6):3580-3589.
33. Ohshima Y, Yang LP, Uchiyama T, Tanaka Y, Baum P, Sergerie M, Hermann P, Delespesse G. OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood 1998, 92(9):3338-3345.
34. Hoshino A, Tanaka Y, Akiba H, Asakura Y, Mita Y, Sakurai T, Takaoka A, Nakaike S, Ishii N, Sugamura K, et al. Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma. Eur J Immunol 2003, 33(4):861-869. 10.1002/eji.200323455, 12672051.
35. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003, 100(10):5986-5990. 10.1073/pnas.1035999100, 156313, 12721360.
36. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103(9):1345-1352. 10.1172/JCI5703, 408356, 10225978.
37. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003, 52(1):65-70. 10.1136/gut.52.1.65, 1773503, 12477762.
38. Zhu Z, Ma B, Zheng T, Homer RJ, Lee CG, Charo IF, Noble P, Elias JA. IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 2002, 168(6):2953-2962.
39. Daley E, Emson C, Guignabert C, de Waal Malefyt R, Louten J, Kurup VP, Hogaboam C, Taraseviciene-Stewart L, Voelkel NF, Rabinovitch M, et al. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med 2008, 205(2):361-372. 10.1084/jem.20071008, 2271018, 18227220.
40. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000, 67(3):737-744. 10.1086/303059, 1287532, 10903931.
41. Morse JH, Deng Z, Knowles JA. Genetic aspects of pulmonary arterial hypertension. Ann Med 2001, 33(9):596-603. 10.3109/07853890109002105, 11817654.
42. Quinlan TR, Li D, Laubach VE, Shesely EG, Zhou N, Johns RA. eNOS-deficient mice show reduced pulmonary vascular proliferation and remodeling to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 2000, 279(4):L641-650.
43. Steudel W, Scherrer-Crosbie M, Bloch KD, Weimann J, Huang PL, Jones RC, Picard MH, Zapol WM. Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3. J Clin Invest 1998, 101(11):2468-2477. 10.1172/JCI2356, 508836, 9616218.
44. Droma Y, Hanaoka M, Ota M, Katsuyama Y, Koizumi T, Fujimoto K, Kobayashi T, Kubo K. Positive association of the endothelial nitric oxide synthase gene polymorphisms with high-altitude pulmonary edema. Circulation 2002, 106(7):826-830. 10.1161/01.CIR.0000024409.30143.70, 12176955.
45. Ono M, Sawa Y, Mizuno S, Fukushima N, Ichikawa H, Bessho K, Nakamura T, Matsuda H. Hepatocyte growth factor suppresses vascular medial hyperplasia and matrix accumulation in advanced pulmonary hypertension of rats. Circulation 2004, 110(18):2896-2902. 10.1161/01.CIR.0000146342.30470.30, 15505094.
46. Ito W, Kanehiro A, Matsumoto K, Hirano A, Ono K, Maruyama H, Kataoka M, Nakamura T, Gelfand EW, Tanimoto M. Hepatocyte growth factor attenuates airway hyperresponsiveness, inflammation, and remodeling. Am J Respir Cell Mol Biol 2005, 32(4):268-280. 10.1165/rcmb.2004-0058OC, 15626778.
47. Niedbala W, Wei XQ, Campbell C, Thomson D, Komai-Koma M, Liew FY. Nitric oxide preferentially induces type 1 T cell differentiation by selectively up-regulating IL-12 receptor beta 2 expression via cGMP. Proc Natl Acad Sci USA 2002, 99(25):16186-16191. 10.1073/pnas.252464599, 138586, 12451176.
48. Ivy DD, McMurtry IF, Colvin K, Imamura M, Oka M, Lee DS, Gebb S, Jones PL. Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptor-deficient rats: a new model of severe pulmonary arterial hypertension. Circulation 2005, 111(22):2988-2996. 10.1161/CIRCULATIONAHA.104.491456, 1934986, 15927975.